Skip to main content

Table 3 Effect of NVP-AEW541 (IC70) on the cell cycle distribution of pancreatic cancer cell lines

From: Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

Cell line/treatment

Sub-G1

G0/G1

S

G2/M

BxPc3

    

Control

7.7±1.4

55.6±2.3

25.4±5

10.8±1.8

NVP-AEW541

7.9±2.7

69.7±4.5*

15.7±2.9

6.2±1.1

AsPC-1

    

Control

1±0.02

46.1±0.3

31.8±0.2

19.5±0.1

NVP-AEW541

3.9±0.2*

47.1±0.4

35.7±1.5

14±2.6

Capan-1

    

Control

3.8±0.3

50.6±2.5

25.5±3.1

18.6±1.1

NVP-AEW541

7±0.2*

53.6±1.3

23±1.8

15.1±1.4

PT45

    

Control

2.3±0.6

74.4±4.3

12.3±2.8

10.1±1

NVP-AEW541

10.2±2.7*

59.8±1.4*

19.7±4.8

9.9±2.4

Miapaca-2

    

Control

4.6±2.6

76.1±2.2

10±1.3

8.6±0.5

NVP-AEW541

5.5±2.7

81±1.3

9.4±0.8

4.5±3.7

PANC1

    

Control

5.6±1.5

48.3±4.6

11.6±0.1

32.7±4.7

NVP-AEW541

9.3±0.5

72.4±2.1*

12.1±0.3

4.9±0.4*

FA6

    

Control

13.8±2

48.3±3.1

25.4±4.8

11.2±0.4

NVP-AEW541

36.8±2.8*

33.2±1.2*

22.2±1.3

6.9±2.2

  1. Each population is expressed as percentage of gated cells (mean of three independent experiments ± S.D).* depicts statistically significant difference (p<0.05) compared to control values.